Benjamin E. Leiby, Ph.D.
Affiliations: | 2006 | University of Pennsylvania, Philadelphia, PA, United States |
Area:
Biostatistics BiologyGoogle:
"Benjamin Leiby"Parents
Sign in to add mentor| Mary D. Sammel | grad student | 2006 | Penn | |
| (Bayesian multivariate growth curve latent class models.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Luginbuhl A, Johnson JM, Harshyne L, et al. (2020) Window-of-opportunity trial of nivolumab with or without the IDO inhibitor BMS-986205 in patients with resectable squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology. 38: TPS6595-TPS6595 |
| Sokol K, Rhoades R, Leiby BE, et al. (2019) Comprehensive geriatric assessment prior to autologous stem cell transplant as a predictor of patient outcomes: A retrospective review. Journal of Clinical Oncology. 37: e23023-e23023 |
| Luginbuhl A, Johnson J, Harshyne L, et al. (2019) A window of opportunity trial of preoperative nivolumab with or without tadalafil in squamous cell carcinoma of the head and neck (SCCHN): Safety, clinical, and correlative outcomes Annals of Oncology. 30: v453 |
| Godwin JL, Hoffman-Censits JH, Den RB, et al. (2018) c15-162: Phase IB trial of radium 223 and niraparib in patients with castrate resistant prostate cancer (NiraRad). Journal of Clinical Oncology. 36 |
| McNair C, Xu K, Mandigo AC, et al. (2018) Abstract IA03: Differential impact of RB pathway status on E2F1 reprogramming and disease progression in human prostate cancer Cancer Research. 78 |
| Williams NL, Nowak-Choi K, Skowronski J, et al. (2017) Evaluating the effect of therapy duration on survival in patients with metastatic castration-resistant prostate cancer receiving radium-223. Journal of Clinical Oncology. 35: e593-e593 |
| Tatarian T, Jiang W, Leiby BE, et al. (2016) Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial. Annals of Surgery |
| Lin J, Sama AR, Hoffman-Censits JH, et al. (2016) A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone. Journal of Clinical Oncology. 34: 311-311 |
| Leiby BE, Ten Have TR, Lynch KG, et al. (2014) Bayesian multivariate growth curve latent class models for mixed outcomes. Statistics in Medicine. 33: 3434-52 |
| Mirtti T, Leiby BE, Abdulghani J, et al. (2013) Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy. Human Pathology. 44: 310-9 |